Tag: Spdr S&P Biotech Etf
-
AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports
U.K. pharmaceutical giant AstraZeneca is considering a deal to merge with its U.S. rival Bristol Myers Squibb.
-
Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials
There are now positive results from five late-stage trials on retatrutide, which Lilly is positioning as the next pillar of its obesity portfolio.
-
Biotech remains compelling even after major comeback. Here’s what investors say
The healthcare subsector has quietly become one of the most attractive opportunities this year.
-
Wall Street can wait: Why one U.S. biotech firm is listing in Hong Kong first
Global biotech firms are increasingly being drawn to Hong Kong for its growing investor base and proximity to Chinese pharmaceutical partners.
-
Plenty of stocks are working in this market — you just have to look beyond tech
The big unanswered question is how long there can be such terrific opportunities outside tech before it dawns on those overweight the sector.
-
AstraZeneca’s trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?
For years, AstraZeneca has commanded one of the richest valuations among large European pharma companies on the assumption that it consistently delivers results.
-
BTIG names an athleisure company, cybersecurity stock and more as its top picks for the second half of 2026
The firm named 55 large- and small-cap stocks that it thinks are set to perform well in the next six months.
-
The charts on this biotech stock look attractive, says Jay Woods
The chief market strategist at Freedom Capital Markets breaks down the technicals in this biotech name.
-
Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBC
Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.
-
GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT
The deal comes at a time of biotech dealmaking frenzy, driven by looming patent cliffs, newly buoyant public markets and drugmakers’ race to bolster pipelines.
Latest News
Stay Connected
Categories
BBC News CNA CNBC CNN International Deutsche Welle (DW) Euronews France 24 General Global & European Specialized & Regional
Tags
amp Artificial intelligence Asia Breaking News: Business Breaking News: Markets Breaking News: Politics Breaking News: Technology Business business news cent china cup Donald J. Trump Donald Trump economy European Union fast football France germany Investment strategy iran Iran war markets news People per politics return russia said Singapore spain Sport Stock markets technology trump ukraine United States US-Israel attack on Iran 2026 video War in Ukraine World world cup World Cup 2026
About the Author
AF themes
Easy WordPress Websites Builder: Versatile Demos for Blogs, News, eCommerce and More – One-Click Import, No Coding! 1000+ Ready-made Templates for Stunning Newspaper, Magazine, Blog, and Publishing Websites.
Search the Archives
Access over the years of investigative journalism and breaking reports
You May Have Missed
